The Insight Partners Latest Research on “Small Molecule Drug Discovery Market Forecast to 2027″ Includes COVID-19 Impact and Global Analysis by Therapeutic Area (Oncology, Central Nervous System, Cardiovascular, Respiratory, Orthopedics, Immunology, Rare Diseases, and Other Therapeutic Areas); Process/Phase (Target Discovery, Target Validation, Lead Generation and Refinement, and Preclinical Development); and Geography
“Small Molecule Drug Discovery Market was valued at US$ 24,976.14 million in 2019 and is projected to reach US$ 50,823.06 million by 2027; it is expected to grow at a CAGR of 9.5% during 2020–2027. The report highlights trends prevailing in the global small molecule drug discovery market and the factors driving market along with those that act as hindrances.
Download PDF Sample Copy at: https://www.theinsightpartners.com/sample/TIPRE00004774/
Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and cost affectivity.
Top Players Analysis:
Market leaders operating in the market have undertaken various organic growth strategies in the small molecule drug discovery Market. The small molecule drug discovery market majorly consists of the players such as Pfizer Inc., Bristol-Myers Squibb Company, Merck KGaA, GlaxoSmithKline Plc, AstraZeneca, Johnson & Johnson Services, Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Boehringer Ingelheim International GmbH, and Allergan Plc. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the small molecule drug discovery market:
Jan-20: Merck KGaa entered into exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., and Astex Pharmaceuticals, a UK based company. This partnership aims to improve small-molecule inhibitors toward several drug targets, such as KRAS oncogene, and others which are currently under-investigated for the treatment of cancer
Dec-19: AstraZeneca linked up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve the productivity of its automated compound synthesis operations. AstraZeneca aims to use DeepMatter’s platform to replay and explore its chemical synthesis reactions digitally and to uncover methods to save time and resources as it builds single compounds or larger libraries
Ask for Discount at: https://www.theinsightpartners.com/discount/TIPRE00004774/
Jul-19: Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered a strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing
Segments:
Based on process/phase, the global small molecule drug discovery market is segmented into target discovery, target validation, lead generation and refinement, and preclinical development. The lead generation and refinement segment held the largest share of the global small molecule drug discovery market in 2019. However, the target discovery is anticipated to register the highest CAGR during the forecast period. The target discovery segment is expected to grow owing to increasing demand of therapeutics, increasing product approvals, and rising investment in the drug discovery process.
Based on therapeutic area, the global small molecule drug discovery market is segmented into oncology, central nervous system, cardiovascular, respiratory, orthopedics, immunology, rare diseases, and other therapeutic areas. The oncology cells segment held a largest share of the market in 2019; however, the rare diseases segment is estimated to register a higher CAGR during the forecast period owing to increasing prevalence of rare diseases, research activities and collaborations among market players. Some of the rare diseases are Hutchinson-Gilford Progeria, Fibrodysplasia Ossificans Progressiva, Microcephaly, Morgellons, and others.
Buy Report at: https://www.theinsightpartners.com/buy/TIPRE00004774/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876